Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Gabriella Moroni is active.

Publication


Featured researches published by Gabriella Moroni.


Experimental Cell Research | 2009

The activation of human endogenous retrovirus K (HERV-K) is implicated in melanoma cell malignant transformation

A Serafino; Emanuela Balestrieri; P Pierimarchi; Claudia Matteucci; Gabriella Moroni; E. Oricchio; G Rasi; Antonio Mastino; Corrado Spadafora; Enrico Garaci; P. Sinibaldi Vallebona

Melanoma development is a multi-step process arising from a series of genetic and epigenetic events. Although the sequential stages involved in progression from melanocytes to malignant melanoma are clearly defined, our current understanding of the mechanisms leading to melanoma onset is still incomplete. Growing evidence show that the activation of endogenous retroviral sequences might be involved in transformation of melanocytes as well as in the increased ability of melanoma cells to escape immune surveillance. Here we show that human melanoma cells in vitro undergo a transition from adherent to a more malignant, non-adherent phenotype when exposed to stress conditions. Melanoma-derived non-adherent cells are characterized by an increased proliferative potential and a decreased expression of both HLA class I molecules and Melan-A/MART-1 antigen, similarly to highly malignant cells. These phenotypic and functional modifications are accompanied by the activation of human endogenous retrovirus K expression (HERV-K) and massive production of viral-like particles. Down-regulation of HERV-K expression by RNA interference prevents the transition from the adherent to the non-adherent growth phenotype in low serum. These results implicate HERV-K in at least some critical steps of melanoma progression.


Biochemical Journal | 2011

Treatment of doxorubicin-resistant MCF7/Dx cells with nitric oxide causes histone glutathionylation and reversal of drug resistance

Anastasia De Luca; Noemi Moroni; Annalucia Serafino; Alessandra Primavera; Anna Pastore; Jens Z. Pedersen; Raffaele Petruzzelli; Maria Grazia Farrace; Pasquale Pierimarchi; Gabriella Moroni; Giorgio Federici; Paola Sinibaldi Vallebona; Mario Lo Bello

Acquired drug resistance was found to be suppressed in the doxorubicin-resistant breast cancer cell line MCF7/Dx after pre-treatment with GSNO (nitrosoglutathione). The effect was accompanied by enhanced protein glutathionylation and accumulation of doxorubicin in the nucleus. Among the glutathionylated proteins, we identified three members of the histone family; this is, to our knowledge, the first time that histone glutathionylation has been reported. Formation of the potential NO donor dinitrosyl-diglutathionyl-iron complex, bound to GSTP1-1 (glutathione transferase P1-1), was observed in both MCF7/Dx cells and drug-sensitive MCF7 cells to a similar extent. In contrast, histone glutathionylation was found to be markedly increased in the resistant MCF7/Dx cells, which also showed a 14-fold higher amount of GSTP1-1 and increased glutathione concentration compared with MCF7 cells. These results suggest that the increased cytotoxic effect of combined doxorubicin and GSNO treatment involves the glutathionylation of histones through a mechanism that requires high glutathione levels and increased expression of GSTP1-1. Owing to the critical role of histones in the regulation of gene expression, the implication of this finding may go beyond the phenomenon of doxorubicin resistance.


The FASEB Journal | 2004

Differentiation of human melanoma cells induced by cyanidin-3-O-β-glucopyranoside

Annalucia Serafino; Paola Sinibaldi-Vallebona; Giuseppe Lazzarino; Barbara Tavazzi; Guido Rasi; Pasquale Pierimarchi; Federica Andreola; Gabriella Moroni; Giacomo Galvano; Fabio Galvano; Enrico Garaci

Great attention has been recently given to a flavonoid of the anthocyanin class, cyanidin‐3‐O‐β‐ glucopyranoside (C‐3‐G), which is widely spread throughout the plant kingdom, and is present in both fruits and vegetables of human diets. In this study, we investigated the effect of C‐3‐G on proliferation and differentiation of human melanoma cells. Both morphological and functional parameters were evaluated, using electron and confocal microscopy, cytofluorometric analysis, HPLC assay, Western blot analysis, and enzymatic assay, as appropriate. A treatment with a single dose of C‐3‐G decreased cell proliferation without affecting cell viability and without inducing apoptosis or necrosis. The mitotic index and cell percentage in S phase were significantly lower in C‐3‐G treated cells compared with untreated control. C‐3‐G treatment induced, in a dose‐ and time‐dependent manner, melanoma cell differentiation characterized by a strong increase in dendrite outgrowth accompanied with a remodeling of the microtubular network, a dramatic increase of focal adhesion and an increased expression of “brain specific” cytoskeletal components such as NF‐160 and NF‐200 neurofilament proteins. C‐3‐G treatment also induced increase of cAMP levels and up‐regulation of tyrosinase expression and activity resulting in an enhanced melanin synthesis and melanosome maturation. Up‐regulation of the melanoma differentiation antigen Melan‐A/MART‐1 in treated cells respect to the untreated control was also recorded. Data obtained provide evidence that a single treatment with C‐3‐G is able to revert the human melanoma cells from the proliferating to the differentiated state. We conclude that C‐3‐G is a very promising molecule to include in the strategies for treatment of melanoma; also because of its nutritional relevance.


Annals of the New York Academy of Sciences | 2012

Thymosin α1 and cancer: action on immune effector and tumor target cells

Enrico Garaci; Francesca Pica; Annalucia Serafino; Emanuela Balestrieri; Claudia Matteucci; Gabriella Moroni; R Sorrentino; Manuela Zonfrillo; Pasquale Pierimarchi; Paola Sinibaldi-Vallebona

Since it was first identified, thymosin alpha 1 (Tα1) has been characterized to have pleiotropic effects on several pathological conditions, in particular as a modulator of immune response and inflammation. Several properties exerted by Tα1 may be attributable to a direct action on lymphoid cells. Tα1 has been shown to exert an immune modulatory activity on both T cell and natural killer cell maturation and to have an effect on functions of mature lymphocytes, including stimulating cytokine production and cytotoxic T lymphocyte–mediated cytotoxic responses. In previous studies we have shown that Tα1 increases the expression of major histocompatibility complex class I surface molecules in murine and human tumor cell lines and in primary cultures of human macrophages. In the present paper, we describe preliminary data indicating that Tα1 is also capable of increasing the expression of tumor antigens in both experimental and human tumor cell lines. This effect, which is exerted at the level of the target tumor cells, represents an additional factor increasing the antitumor activity of Tα1.


Anti-Cancer Drugs | 2012

Antitumor effects of the benzophenanthridine alkaloid sanguinarine in a rat syngeneic model of colorectal cancer.

Francesca Pica; Emanuela Balestrieri; Annalucia Serafino; R Sorrentino; Roberta Gaziano; Gabriella Moroni; Noemi Moroni; Graziana Palmieri; Maurizio Mattei; Enrico Garaci; Paola Sinibaldi-Vallebona

To evaluate the in-vivo preclinical antitumor activity of sanguinarine in a rat syngeneic model of colorectal cancer. The effects of sanguinarine on DHD/K12/TRb colorectal adenocarcinoma cells were first evaluated in vitro by means of 3H-thymidine incorporation, 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium) (MTS) assay, and terminal transferase dUTP nick end labeling (TUNEL) microscopy. For the in-vivo studies, DHD/K12/TRb cells (1.5×106 cells/0.3 ml of sterile saline/animal) were injected subcutaneously in syngeneic BDIX rats, which were chronically treated with sanguinarine (5 mg/kg/day per os) or control diluent. Tumor growth, body weight, hematologic, and clinical chemistry measurements were monitored in individual animals at defined time intervals. After killing, subcutaneous tumors were explanted from experimental animals for histopathological examination. In vitro, micromolar concentrations of sanguinarine inhibited dose-dependently DHD/K12/TRb cell proliferation and metabolism and induced cell death by apoptosis. In vivo, oral administration of sanguinarine induced a significant inhibition of tumor growth (P<0.01 vs. untreated controls), in the absence of any toxic or side effects. Marked apoptosis and reduced peritumoral vascularization were observed in tumors from sanguinarine-treated rats as compared with the controls. Additional basic studies are needed to fully characterize the mechanism/s underlying the inhibitory effects of sanguinarine on angiogenesis and tumor growth as well as the pharmacological and safety profile of this drug in experimental tumor models. Overall, findings from this study suggest that sanguinarine is a likely candidate for further evaluation in cancer therapy.


Journal of Innate Immunity | 2014

Thymosin α1 activates complement receptor-mediated phagocytosis in human monocyte-derived macrophages

Annalucia Serafino; Francesca Pica; Federica Andreola; Roberta Gaziano; Noemi Moroni; Gabriella Moroni; Manuela Zonfrillo; Pasquale Pierimarchi; Paola Sinibaldi-Vallebona; Enrico Garaci

Thymosin α1 (Tα1) is a naturally occurring thymic peptide used worldwide in clinical trials for the treatment of infectious diseases and cancer. The immunomodulatory activity of Tα1 on innate immunity effector cells has been extensively described, but its mechanism of action is not completely understood. We report that Tα1-exposed human monocyte-derived macrophages (MDMs) assume the typical activated morphology also exhibited by lipopolysaccharide-activated MDMs, but show a comparatively higher ability of internalizing fluorescent beads and zymosan particles. Tα1 exposure also promptly and dramatically stimulates MDM phagocytosis and killing of Aspergillus niger conidia starting as soon as 30 min after challenge. The effect is dose dependent and early coupled to low transcription of the proinflammatory cytokines tumor necrosis factor α and interleukin-6 and unmodified Toll-like receptor expression. The Tα1-stimulated phagocytosis is strictly dependent on the integrity of the microtubule network and protein kinase C activity and occurs by a variation in the classic zipper model, with recruitment of vinculin and actin at the phagosome exhibiting a punctate distribution. These findings indicate that, in human mature MDMs, Tα1 implements pathogen internalization and killing via the stimulation of the complement receptor-mediated phagocytosis. Our observations document that Tα1 is an early and potent activator of innate immunity and reinforce the concept of its pleiotropy.


World Journal of Gastrointestinal Oncology | 2016

Antitumor effects of the benzophenanthridine alkaloid sanguinarine: Evidence and perspectives

Roberta Gaziano; Gabriella Moroni; Miele Mt; Paola Sinibaldi-Vallebona; Francesca Pica

Historically, natural products have represented a significant source of anticancer agents, with plant-derived drugs becoming increasingly explored. In particular, sanguinarine is a benzophenanthridine alkaloid obtained from the root of Sanguinaria canadensis, and from other poppy Fumaria species, with recognized anti-microbial, anti-oxidant and anti-inflammatory properties. Recently, increasing evidence that sanguinarine exibits anticancer potential through its capability of inducing apoptosis and/or antiproliferative effects on tumor cells, has been proved. Moreover, its antitumor seems to be due not only to its pro-apoptotic and inhibitory effects on tumor growth, but also to its antiangiogenic and anti-invasive properties. Although the precise mechanisms underlying the antitumor activity of this compound remain not fully understood, in this review we will focus on the most recent findings about the cellular and molecular pathways affected by sanguinarine, together with the rationale of its potential application in clinic. The complex of data currently available suggest the potential application of sanguinarine as an adjuvant in the therapy of cancer, but further pre-clinical studies are needed before such an antitumor strategy can be effectively translated in the clinical practice.


Retrovirology | 2009

Activation of human endogenous retrovirus K (HERV-K) and cellular modifications in human melanoma cell line: transcriptional profiling analysis

Emanuela Balestrieri; Claudia Matteucci; R Sorrentino; Reem Al Dossary; Annalucia Serafino; Pasquale Pierimarchi; Gabriella Moroni; Enrico Garaci; Paola Sinibaldi Vallebona

Background Similarly to what shown for exogenous tumorigenic retroviruses, endogenous retrovitus (ERVs) have been implicated in the pathogenesis of cancer. ERVs may participate in the process of malignant transformation or promote tumor growth, e.g. through insertional mutagenesis or via counteracting tumor immunosurveillance. Growing evidences show that the activation of endogenous retroviral sequences might be involved in transformation of melanocytes as well as in the increased ability of melanoma cells to escape immune surveillance.


Melanoma Research | 2006

Activation of human endogenous retrovirus-K and production of infectious viral-like particles in human melanoma cells

A Serafino; Emanuela Balestrieri; P Pierimarchi; Claudia Matteucci; G Rasi; Gabriella Moroni; Mastino A; E Garaci; P. Sinibaldi Vallebona

Background and Aim Melanoma development is a multistep process arising from a series of genetic and epigenetic events including cell transformation and change in the interactions between the transformed cells and the host. Despite the clearly defined sequential stages involved in the progression from melanocytes to malignant melanoma, little is known about the mechanisms leading to melanoma insurgence and progression. Growing evidence shows that the activation of endogenous retroviral sequences could be involved in the transformation of melanocytes and in the increasing ability of melanoma cells to escape immune surveillance. The aim of the present study has been to verify whether the melanocytes transformation is accompanied with a de novo synthesis of infectious viral-like particles of human endogenous retrovirus K (HERV-K).


Expert Opinion on Biological Therapy | 2018

Serum thymosin alpha 1 levels in normal and pathological conditions

Francesca Pica; Roberta Gaziano; Ida A. Casalinuovo; Gabriella Moroni; Dolores Limongi; Cartesio D’Agostini; Carlo Tomino; Roberto Perricone; Anna Teresa Palamara; Paola Sinibaldi Vallebona; Enrico Garaci

ABSTRACT Introduction: Thymosin alpha 1 (Ta1) is a natural occurring peptide hormone that is crucial for the maintenance of the organism homeostasis. It has been chemically synthesized and used in diseases where the immune system is hindered or malfunctioning. Areas covered: Many clinical trials investigate the Ta1 effects in patients with cancer, infectious diseases and as a vaccine enhancer. The number of diseases that could benefit from Ta1 treatment is increasing. To date, questions remain about the physiological basal levels of Ta1 and the most effective dose and schedule of treatment. Evidence is growing that diseases characterized by deregulation of immune and/or inflammatory responses are associated with serum levels of Ta1 significantly lower than those of healthy individuals: to date, B hepatitis, psoriatic arthritis, multiple sclerosis and sepsis. The sputum of cystic fibrosis patients contains lower levels of Ta1 than healthy controls. These data are consistent with the role of Ta1 as a regulator of immunity, tolerance and inflammation. Expert opinion: Low serum Ta1 levels are predictive and/or associated with different pathological conditions. In case of Ta1 treatment, it is crucial to know the patient’s baseline serum Ta1 level to establish effective treatment protocols and monitor their effectiveness over time.

Collaboration


Dive into the Gabriella Moroni's collaboration.

Top Co-Authors

Avatar

Emanuela Balestrieri

University of Rome Tor Vergata

View shared research outputs
Top Co-Authors

Avatar

A Serafino

University of Rome Tor Vergata

View shared research outputs
Top Co-Authors

Avatar

Claudia Matteucci

University of Rome Tor Vergata

View shared research outputs
Top Co-Authors

Avatar

Enrico Garaci

University of Rome Tor Vergata

View shared research outputs
Top Co-Authors

Avatar

Francesca Pica

University of Rome Tor Vergata

View shared research outputs
Top Co-Authors

Avatar

P Pierimarchi

University of Rome Tor Vergata

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Noemi Moroni

National Research Council

View shared research outputs
Researchain Logo
Decentralizing Knowledge